Laboratory Corporation of America: Glial Fibrillary Acidic Protein

Laboratory Corporation of America this week introduced its glial fibrillary acidic protein (GFAP) test, a blood-based immunoassay to aid in the early detection of neurodegenerative diseases and neurological injuries. The test can be used to assess the presence of progress of conditions such as Alzheimer's disease, multiple sclerosis, glioblastoma, and traumatic brain injury.